A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (Temsr) Regimens In Subjects With Relapsed, Refractory Mantle Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Temsirolimus (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 11 Apr 2017 Planned End Date changed from 1 Oct 2017 to 15 Jun 2018.
- 11 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Dec 2016 Results (n=90) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology